InSilico Medicine Launches Hong Kong IPO

MT Newswires Live

12/18

InSilico Medicine (HKG:3696) launched its initial public offering in Hong Kong to raise HK$2.28 billion.

The Boston-based biotechnology firm is offering nearly 94.7 million shares at an indicative price of HK$24.05 apiece, according to a bourse filing Thursday.

The issuer expects to disclose allocations on Dec. 29 and begin trading on the Hong Kong bourse on Dec. 30.

The company secured 16 cornerstone investors who committed to buying $115 million worth of IPO shares.

InSilico Medicine will use the IPO proceeds to fund clinical research and development of its drug candidates, develop generative artificial intelligence models, expand its automated lab, and for working capital.

Morgan Stanley, China International Capital Corp., GF Securities (Hong Kong), BNP Paribas Securities (Asia), Sinolink Securities (Hong Kong), and BOCI Asia are the joint bookrunners of the IPO.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2592928946"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592928946\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592928946?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 10:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592928946","market":"us","top_or_hot":-1,"title":"InSilico Medicine Launches Hong Kong IPO","media":"MT Newswires Live","content":"<html><body><p> InSilico Medicine (HKG:3696) launched its initial public offering in Hong Kong to raise HK$2.28 billion.</p><p>The Boston-based biotechnology firm is offering nearly 94.7 million shares at an indicative price of HK$24.05 apiece, according to a bourse filing Thursday.</p><p>The issuer expects to disclose allocations on Dec. 29 and begin trading on the Hong Kong bourse on Dec. 30.</p><p>The company secured 16 cornerstone investors who committed to buying $115 million worth of IPO shares.</p><p>InSilico Medicine will use the IPO proceeds to fund clinical research and development of its drug candidates, develop generative artificial intelligence models, expand its automated lab, and for working capital.</p><p>Morgan Stanley, China International Capital Corp., <a href=\"https://laohu8.com/S/GFSEF\">GF Securities</a> (Hong Kong), BNP Paribas Securities (Asia), <a href=\"https://laohu8.com/S/600109\">Sinolink Securities</a> (Hong Kong), and BOCI Asia are the joint bookrunners of the IPO.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InSilico Medicine Launches Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInSilico Medicine Launches Hong Kong IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-18 10:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> InSilico Medicine (HKG:3696) launched its initial public offering in Hong Kong to raise HK$2.28 billion.</p><p>The Boston-based biotechnology firm is offering nearly 94.7 million shares at an indicative price of HK$24.05 apiece, according to a bourse filing Thursday.</p><p>The issuer expects to disclose allocations on Dec. 29 and begin trading on the Hong Kong bourse on Dec. 30.</p><p>The company secured 16 cornerstone investors who committed to buying $115 million worth of IPO shares.</p><p>InSilico Medicine will use the IPO proceeds to fund clinical research and development of its drug candidates, develop generative artificial intelligence models, expand its automated lab, and for working capital.</p><p>Morgan Stanley, China International Capital Corp., <a href=\"https://laohu8.com/S/GFSEF\">GF Securities</a> (Hong Kong), BNP Paribas Securities (Asia), <a href=\"https://laohu8.com/S/600109\">Sinolink Securities</a> (Hong Kong), and BOCI Asia are the joint bookrunners of the IPO.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2592928946","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592928946","pubTimestamp":1766023317,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"InSilico Medicine  launched its initial public offering in Hong Kong to raise HK$2.28 billion.The Boston-based biotechnology firm is offering nearly 94.7 million shares at an indicative price of HK$24.05 apiece, according to a bourse filing Thursday.The issuer expects to disclose allocations on Dec. 29 and begin trading on the Hong Kong bourse on Dec. 30.The company secured 16 cornerstone investors who committed to buying $115 million worth of IPO shares.InSilico Medicine will use the IPO proceeds to fund clinical research and development of its drug candidates, develop generative artificial intelligence models, expand its automated lab, and for working capital.Morgan Stanley, China International Capital Corp., GF Securities , BNP Paribas Securities , Sinolink Securities , and BOCI Asia are the joint bookrunners of the IPO.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"InSilico Medicine启动香港IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":0.9},"content_text":"InSilico Medicine (HKG:3696) launched its initial public offering in Hong Kong to raise HK$2.28 billion.The Boston-based biotechnology firm is offering nearly 94.7 million shares at an indicative price of HK$24.05 apiece, according to a bourse filing Thursday.The issuer expects to disclose allocations on Dec. 29 and begin trading on the Hong Kong bourse on Dec. 30.The company secured 16 cornerstone investors who committed to buying $115 million worth of IPO shares.InSilico Medicine will use the IPO proceeds to fund clinical research and development of its drug candidates, develop generative artificial intelligence models, expand its automated lab, and for working capital.Morgan Stanley, China International Capital Corp., GF Securities (Hong Kong), BNP Paribas Securities (Asia), Sinolink Securities (Hong Kong), and BOCI Asia are the joint bookrunners of the IPO.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}